Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Schulz

Showing results (841-850 of 906) with videos related to

Pageof 91
Sort By:
Neurological Research and Practice|December 16, 2020
Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)Kathrin Reetz, Ralf-Dieter Hilgers, Susanne Isfort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2016
Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE studyElke Kalbe, Sarah Petra Rehberg, Ines Heber, et al.
Orphanet Journal of Rare Diseases|September 11, 2014
Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathiesAnna-Lena Semmler, Sabrina Sacconi, J Elisa Bach, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2023
Predictors of Survival in Friedreich's Ataxia: A Prospective Cohort StudyElisabetta Indelicato, Kathrin Reetz, Sarah Maier, et al.
The Lancet. Neurology|March 26, 2021
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort studyKathrin Reetz, Imis Dogan, Ralf-Dieter Hilgers, et al.
Journal of Parkinson'S Disease|July 31, 2025
Progression to Parkinson's dementia is not modulated by genetic risk variants for Alzheimer's or Parkinson's diseaseKayenat Parveen, J Alexander Ross, Hendrik van der Wurp, et al.
Orphanet Journal of Rare Diseases|May 12, 2017
Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 casesLukas J Schnitzler, Tobias Schreckenbach, Aleksandra Nadaj-Pakleza, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2025
Analysis of a Modified Version of the Inventory of Non-Ataxia Signs Over 12 Years in Patients with Friedreich's Ataxia in the EFACTS StudyStella Andrea Lischewski, Imis Dogan, Paola Giunti, et al.
Annals of Clinical and Translational Neurology|August 29, 2023
Longitudinal changes of SARA scale in Friedreich ataxia: Strong influence of baseline score and age at onsetLuca Porcu, Mario Fichera, Lorenzo Nanetti, et al.
Human Molecular Genetics|March 7, 2003
Transgenic rat model of Huntington's diseaseStephan von Hörsten, Ina Schmitt, Huu Phuc Nguyen, et al.
Pageof 91

Showing results (841-850 of 906) with videos related to

Sort By:
Pageof 91
Neurological Research and Practice|December 16, 2020
Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)Kathrin Reetz, Ralf-Dieter Hilgers, Susanne Isfort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2016
Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE studyElke Kalbe, Sarah Petra Rehberg, Ines Heber, et al.
Orphanet Journal of Rare Diseases|September 11, 2014
Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathiesAnna-Lena Semmler, Sabrina Sacconi, J Elisa Bach, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2023
Predictors of Survival in Friedreich's Ataxia: A Prospective Cohort StudyElisabetta Indelicato, Kathrin Reetz, Sarah Maier, et al.
The Lancet. Neurology|March 26, 2021
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort studyKathrin Reetz, Imis Dogan, Ralf-Dieter Hilgers, et al.
Journal of Parkinson'S Disease|July 31, 2025
Progression to Parkinson's dementia is not modulated by genetic risk variants for Alzheimer's or Parkinson's diseaseKayenat Parveen, J Alexander Ross, Hendrik van der Wurp, et al.
Orphanet Journal of Rare Diseases|May 12, 2017
Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 casesLukas J Schnitzler, Tobias Schreckenbach, Aleksandra Nadaj-Pakleza, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2025
Analysis of a Modified Version of the Inventory of Non-Ataxia Signs Over 12 Years in Patients with Friedreich's Ataxia in the EFACTS StudyStella Andrea Lischewski, Imis Dogan, Paola Giunti, et al.
Annals of Clinical and Translational Neurology|August 29, 2023
Longitudinal changes of SARA scale in Friedreich ataxia: Strong influence of baseline score and age at onsetLuca Porcu, Mario Fichera, Lorenzo Nanetti, et al.
Human Molecular Genetics|March 7, 2003
Transgenic rat model of Huntington's diseaseStephan von Hörsten, Ina Schmitt, Huu Phuc Nguyen, et al.
Pageof 91